Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The study seeks to establish the safety of neoadjuvant aromatase inhibitor with:
DPX-Survivac, DPX-Survivac plus radiation, or DPX-Survivac with cyclophosphamide in stage I
to III HR+HER2- breast cancer. There will be sequential enrollment into 3 arms with an
anticipated N=6 participants per arm for N=18 participants in total. All participants will
receive letrozole 2.5 mg daily during the 6 weeks of neoadjuvant therapy. Neoadjuvant therapy
occurs weeks 1-6, with standard of care surgery taking place week 7 to 9.